Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
192 IgG-saporin is a **targeted immunotoxin** composed of the mouse monoclonal antibody **192 IgG**, which specifically binds to the **p75 neurotrophin receptor (NGFR, low-affinity nerve growth factor receptor)**, conjugated to **saporin**, a ribosome-inactivating protein. The antibody component confers selectivity for cholinergic neurons—primarily in the basal forebrain—while the saporin payload induces cell death by irreversibly inactivating ribosomes. This immunotoxin is widely used in neuroscience research to selectively ablate cholinergic neurons in animal models, especially to create models of disorders featuring cholinergic hypofunction, such as **Alzheimer’s disease**, via intracerebroventricular (i.c.v.) injection. The drug’s action leads to memory deficits and other behavioral changes, primarily through the loss of cholinergic input to the hippocampus and cortex, with secondary effects on microglia and non-cholinergic systems[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 192 IgG-saporin.